In breast cancer, the suppression of SOCS1 by miR-155, which is required for effector T cell responses, resulted in enhanced JAK2-STAT3 signaling by more than three-fold, and it was linked to inflammation-driven tumor progression [133]. Here, JAK2 is linked to neoplasm.